Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Screening for Cognitive Dysfunction Risk in SLE

Lupus; ePub 2018 Nov 27; Chalhoub, Luggen

The Montreal Cognitive Assessment Questionnaire (MoCA) appears to be a promising and practical screening tool for identification of patients with systemic lupus erythematosus (SLE) at risk for cognitive dysfunction (CD), according to a recent study. SLE patients fulfilling American College of Rheumatology (ACR) classification criteria were evaluated using the Automated Neuropsychologic Assessment Metrics (ANAM) as the reference standard. The performance characteristics of the MoCA and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) were assessed in comparison with normal controls (NCs) and rheumatoid arthritis (RA) patients. 4 different definitions of CD were utilized. Researchers found:

  • In total, 78 patients were evaluated.
  • MoCA and ANAM scores were significantly correlated (r = 0.51).
  • At the optimal cutoff, the sensitivity of the MoCA was ≥ 90% (depending on definition of CD) vs RA patients and ≥83% vs NCs.
  • ANAM and IQCODE scores did not correlate.
  • IQCODE sensitivities were low for both RA patients and NCs regardless of definition and cutoff used.
Citation:

Chalhoub NE, Luggen ME. Screening for cognitive dysfunction in systemic lupus erythematosus: The Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly. [Published online ahead of print November 27, 2018]. Lupus. doi:10.1177%2F0961203318815299.